Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HART With Chemotherapy for Non-Pineal Supratentorial PNETs
NCT00274911Phase 2Unknown
- Sponsor
- Children's Cancer and Leukaemia Group
- Start
- Feb 2004
- Primary completion
- Mar 2010
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of lomustine, cisplatin and vincristine in supratentorial primitive neuroectodermal tumor (sPNET), sponsored by Children's Cancer and Leukaemia Group. Primary endpoint: Toxicity measured by hematological, gastrointestinal, mucosal, neurological, and skin morbidity. Status: unknown.
02
Drugs
lomustinecisplatinvincristine
03
Conditions
supratentorial primitive neuroectodermal tumor (sPNET)
Beyond the preview
Go deeper on NCT00274911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00274911.